This audit is for higher specialty trainees, usually ST4 and above, choosing whether StudyPRN should be their primary bank for the SCE in Medical Oncology. The short version: StudyPRN is a genuine specialist SCE bank and a strong option for a first pass, with best-of-five items mapped to the official curriculum. Its principal limitation is the same one every finite bank shares, that completion drifts into recognition, so it needs an unseen measurement layer bolted on.
What StudyPRN offers for SCE Medical Oncology right now
StudyPRN specialises in Specialty Certificate Examinations rather than spreading across every UK exam, which shows in the depth of its oncology content. Figures below are vendor-reported and were checked on 20 July 2026.
| Item | Finding (vendor-reported, 20 July 2026) |
|---|---|
| Question count | Around 498 best-of-five MCQs, including 100 assigned to a timed mock exam. |
| Format | Best-of-five, mirroring the SCE format; instant explanations with further reading; images included. |
| Price | £89.00 as displayed; 3, 6 and 12-month access options. Confirm the price for your chosen duration on the product page. |
| Access and extras | 24/7 online access, unlimited resits, revision notes, peer response comparison, query route to the editor, CPD certificate. |
| Authorship | Written by practising medical oncologists, including consultants at a major cancer centre. |
| Adaptive/AI | No proprietary adaptive-difficulty or AI-tutor engine is claimed; revision is filter-driven and self-directed. |
The takeaway is that StudyPRN is built for exactly this exam, which is a meaningful advantage over generic physician banks that touch oncology only lightly. What it is not is an unseen, infinite measurement source: once you have worked through roughly 498 items, your percentages increasingly reflect memory of specific stems.
The exam you are preparing for: the SCE Medical Oncology blueprint
The SCE in Medical Oncology is two papers of 100 best-of-five questions, 200 in total, three hours per paper, one day, computer-based on Surpass, one mark per correct answer, no negative marking. Only the blueprint is specialty-specific.
| Blueprint domain | Indicative questions (of 200) |
|---|---|
| Chemotherapeutic agents | 28 |
| Breast cancer | 23 |
| Lung cancer | 17 |
| Scientific basis of malignancy | 16 |
| Acute oncology | 15 |
| Colorectal and anal cancer | 11 |
| Urothelial and renal cancer | 10 |
| Oesophagogastric, sarcoma, hepatobiliary | 6 to 7 each |
| Clinical research, skin cancer | 6 each |
| Lymphoma, ovarian, uterine and cervical | 5 each |
| Germ cell, carcinoma of unknown primary | 4 each |
| Other (screening, growth factors, analgesia, anti-emetics, CNS, prostate, head and neck) | 25 |
Verify the current blueprint on thefederation.uk; the curriculum was updated in 2021 and counts vary slightly by diet. Note where the marks concentrate: systemic anticancer therapy and acute oncology outweigh any single tumour site.
Live count broken down by blueprint domain
A headline of "498 questions" tells you almost nothing about fitness for purpose; what matters is the distribution against the table above. StudyPRN's own topic index lists categories that map closely to the official domains, which is a good sign, but you should still audit the count you actually attempt per domain rather than the count advertised. With roughly 498 items spread across some 20 domains, high-weight areas such as chemotherapeutic agents may still offer only 40 to 70 unique items, which is enough for a first pass and drilling but not enough to keep generating genuinely unseen practice through repeated mock cycles. Build the blueprint-coverage matrix and populate it with your attempted counts, not the vendor's total.
Sample question style: what the items actually test
On review of the sample set, StudyPRN's oncology items lean toward application rather than bare recall, which suits an SCE. Stems are clinical vignettes of moderate length, giving performance status, histology, stage and molecular results before asking for the next management step or the most likely toxicity. Option lists are of five and are generally plausible, so elimination requires real knowledge rather than pattern spotting. Image and data interpretation appears, though at lower density than the exam's imaging and pathology load, and management-sequencing items, deciding what to do next rather than what the diagnosis is, are well represented. This is the right register for the SCE, where the examiner is usually testing judgement at the point of a decision.
Jurisdiction and recency
The content is UK-oriented and framed around NICE and national practice, which is correct for a Federation examination. Recency is the live risk in oncology more than in any other specialty, because systemic anticancer therapy, biomarker-directed treatment and immunotherapy indications change between diets. On a stratified sample checked on 20 July 2026, the general principles were sound, but any specific drug indication, licensing threshold or line-of-therapy statement should be reconfirmed against the SmPC on the eMC and current NICE technology appraisals rather than trusted from a static explanation. Treat the bank as a scaffold for reasoning, and treat primary sources as the arbiter of current fact.
Format gap: what a standard Q-bank cannot fully prepare
A best-of-five bank prepares you well for factual recall, toxicity recognition and single-step management. It is structurally weaker at four things the SCE genuinely tests. Staging nuance and multidisciplinary sequencing are hard to capture in one stem. Biomarker-directed decisions move faster than any bank can re-author. Rapidly changing therapies, particularly immunotherapy and targeted agents, date quickly. And toxicity management at the level of grading and escalation thresholds needs current guidance, not a fixed answer key. None of this is a criticism unique to StudyPRN; it is the ceiling of the format. The mitigation is to pair the bank with primary-source reading and with unseen measurement so you are not simply memorising one vendor's snapshot of a moving field.
Duplication and contamination
The contamination risk is intrinsic to a finite bank. As you cycle through roughly 498 items two or three times, your rising percentage increasingly measures recognition of specific stems rather than transferable knowledge, and repeated concepts, capecitabine toxicity, neutropenic sepsis, immune-related colitis, recur in near-identical framings. This is not a flaw in StudyPRN so much as a property of any bounded question set, and it is the single strongest argument for a second, unseen source once you have completed a first pass. The signal to watch is the divergence between your repeat accuracy and your first-attempt accuracy on genuinely new items.
Best-fit matrix: where this bank is strongest
| Use case | StudyPRN fit |
|---|---|
| Foundation building | Strong; specialist authorship and UK framing suit early revision. |
| First pass through the blueprint | Strong; the natural primary bank for this exam. |
| Second bank for volume | Limited; a finite set is not the ideal second, unseen source. |
| Retake after a fail | Moderate; useful if you have not exhausted it, weaker if you have. |
| Final unseen simulation | Weak once completed; use a fresh, unseen source instead. |
The pattern is clear. StudyPRN is a strong first bank and drilling resource and a weak final-simulation resource, because a bank you have completed can no longer produce unseen items.
Worked example: a seven-day pattern for busy trainees
This loop uses StudyPRN for content and iatroX as the unseen transfer-measurement layer, with no claim about any internal algorithm.
- Day 1: 40 StudyPRN items in chemotherapeutic agents; log misses by mechanism.
- Day 2: Read around the misses using the SmPC and current NICE appraisals; no new questions.
- Day 3: 40 StudyPRN items in acute oncology and toxicity management.
- Day 4: Re-test Day 1 misses; add 20 image and data-interpretation items.
- Day 5: Read around Day 3 and Day 4 misses.
- Day 6: Timed, mixed, blueprint-proportional 80 to 100 item block. To measure transfer on items StudyPRN has not shown you, sit a fresh timed unseen block in iatroX and compare first-attempt accuracy, not headline percentage.
- Day 7: Light review; set next week's quotas from the Day 6 unseen result.
Decision checklist: continue, supplement, switch or stop
| Situation (measurable) | Action |
|---|---|
| Early in revision, no bank yet | Continue with StudyPRN as your first pass. |
| First-attempt accuracy rising, coverage even across high-weight domains | Continue; do not add tools for novelty. |
| Repeat accuracy far exceeds first-attempt on new items | Supplement with an unseen source; recognition is inflating scores. |
| Bank completed, percentages plateaued high | Switch measurement to a fresh, unseen bank per the two-Q-bank rule. |
| Unseen, timed, mixed first-attempt consistently comfortable | Stop adding volume; move to timed mixed mocks and rest. |
Bottom line
StudyPRN is a credible, specialist first bank for SCE Medical Oncology, written by oncologists and mapped to the UK blueprint, and it is a strong option for foundation building and a first pass. Its limitation is finiteness: once completed, it measures recognition, not readiness. Use it for content, verify fast-moving facts against primary sources, and measure transfer on unseen, timed, blueprint-proportional blocks.
Frequently asked questions
Is StudyPRN enough for SCE Medical Oncology on its own? For a first pass it can carry most of the content load, because it is a specialist bank of around 498 items written by oncologists and mapped to the UK curriculum. It is not sufficient as a sole resource all the way to the exam, because a finite bank cannot keep producing unseen practice, and oncology facts change faster than any static bank; pair it with primary-source reading and an unseen measurement source.
Which SCE Medical Oncology component does StudyPRN not reproduce well? The components hardest for any best-of-five bank to reproduce are rapidly changing systemic anticancer therapy, biomarker-directed decisions, and toxicity management at the level of grading and escalation thresholds, because these move between diets and need current guidance. StudyPRN handles the reasoning register well but cannot, by format, guarantee that every drug indication is current, so confirm specifics against the SmPC and NICE.
How many StudyPRN questions should I complete per day for SCE Medical Oncology? A sustainable target for a trainee working clinically is roughly 30 to 50 unseen items per revision day, always logged by mechanism, with reading days interleaved rather than a continuous high-volume run. The aim is depth of miss-analysis, not raw throughput; 40 well-analysed items beat 100 skimmed ones.
When should I stop using StudyPRN and move to mixed mocks? Move once your first-attempt accuracy is stable and even across the high-weight domains, chemotherapeutic agents, breast, lung and acute oncology, and once repeats are starting to dominate your sessions. At that point single-domain drilling has given what it can, and timed, blueprint-proportional mixed mocks are the better use of the remaining weeks.
How should I combine StudyPRN with iatroX without duplicating practice? Keep the jobs separate. Use StudyPRN to learn and drill the oncology content, and use iatroX only as the unseen measurement layer on fresh, timed blocks you have never attempted, so the second tool tests transfer rather than re-testing the first tool's items. Compare first-attempt to first-attempt across the two, never headline percentage to headline percentage.
Editorial notes and references
Written by Dr Kolawole Tytler, NHS GP and founder of iatroX. Last checked 20 July 2026. Platform figures, including question counts, prices and features, are vendor-reported and change without notice; confirm current details on the product pages before relying on them. Disclosure: iatroX operates a UK question bank and clinical-knowledge platform and therefore competes with the products discussed; iatroX does not publish a specialty-specific SCE Medical Oncology bank, and its role here is confined to cross-specialty knowledge and unseen-MCQ measurement, a job StudyPRN's specialist bank does not claim to provide. Corrections are welcome via the feedback route on iatrox.com.
References: Federation of Royal Colleges of Physicians of the UK, SCE in Medical Oncology and blueprint (thefederation.uk); StudyPRN Medical Oncology SCE product page (studyprn.com); iatroX, Your Q-Bank Percentage Is Not Your Exam Score; iatroX comparison hub.
Run a fresh, timed unseen block in iatroX and decide your next move →